Should gonadotropin releasing hormone analogue be administered to prevent premature ovarian failure in young women with systemic lupus erythematosus on cyclophosphamide therapy?

Archives of Disease in Childhood

Volumn 93, Issue 5, 2008, Pages 444-445

  Sinha, Rajiv ^a   Dionne, Janis M ^a  

^a BC CHILDREN S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GONADORELIN DERIVATIVE; METHYLPREDNISOLONE; ALKYLATING AGENT; GONADORELIN;

ADOLESCENT; CASE REPORT; CLINICAL DECISION MAKING; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FAILURE; NOTE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PUBERTY; PULSATILE DRUG RELEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; ACUTE KIDNEY FAILURE; CHEMICALLY INDUCED DISORDER; REVIEW;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; KIDNEY FAILURE, ACUTE; LUPUS ERYTHEMATOSUS, SYSTEMIC; OVARIAN FAILURE, PREMATURE;

EID: 44349152932     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2007.131334     Document Type: Note

References (12)

1. Blumenfeld Z, Shapiro D, Shteinberg M, et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000;9(6):401-5.
2. Somers EC, Marder W, Christman GM, et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52(9):2761-7.
3. Ataya KM, Valeriote FA, Ramahi-Ataya AJ. Effect of cyclophosphamide on the immature rat ovary. Cancer Res 1989;49(7):1660-4.
4. Langevitz P, Klein L, Pras M, et al. The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol 1992;28(3-4):157-8.
5. Wallace WH, Shalet SM, Tetlow LJ, et al. Ovarian function following the treatment of childhood acute lymphoblastic leukaemia. Med Pediatr Oncol 1993;21(5):333-9.
6. Brunner HI, Bishnoi A, Barron AC, et al. Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus 2006;15(4):198-206.
7. Houssiau F. 30 years of cyclophosphamide: assessing the evidence. Lupus 2007;16(3):212-16.
8. Blumenfeld Z, Avivi I, Rlitter M, et al. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig 1999;6(5):229-39.
9. Blumenfeld Z. Gynaecologic concerns for young women exposed to gonadotoxic chemotherapy. Curr Opin Obstet Gynecol 2003;15(5):359- 70.
10. Silva CA, Leal MM, Leone C, et al. Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus. Lupus 2002;11(7):419-25.
11. Carreno L, Lopez-Longo FJ, Monteagudo I, et al. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus 1999;8(4):287-92.
12. Chapman RM. Effects of cytotoxic therapy on sexuality and gonadal function. Semin Oncol 1982;9(1):84-94.